Mustang Bio (MBIO) vs Moolec Science SA (MLEC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mustang Bio is the larger company by market cap ($3.2 million vs $3.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBIO | MLEC |
|---|---|---|
| Share price | $0.417 | $4.19 |
| Market cap | $3.16M | $3.04M |
| 1-day change | -7.37% | -12.89% |
| EPS (TTM) | $-0.40 | $-173.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.81 | $23.22 |
| 52-week low | $0.41 | $3.08 |
| Distance from 52-week high | -76.96% | -81.96% |
| Average volume | 29.38K | 17.09K |
| Shares outstanding | 6.73M | 726.12K |
| Employees | 4 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Healthcare · Biotechnology · 4 employees
About Moolec Science SA
MLEC stock →Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas.
Healthcare · Biotechnology
MBIO vs MLEC FAQ
Which is bigger, Mustang Bio or Moolec Science SA?
Mustang Bio (MBIO) is larger, with a market capitalization of $3.16M compared with $3.04M for Moolec Science SA (MLEC).
Are Mustang Bio and Moolec Science SA in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.